diABZI STING agonist-1 (trihydrochloride)
CAT:
804-HY-112921B-04
Size:
50 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
diABZI STING agonist-1 (trihydrochloride)
- CAS Number: 2138299-34-8
- UNSPSC Description: diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
- Target Antigen: STING
- Type: Reference compound
- Related Pathways: Immunology/Inflammation
- Applications: COVID-19-immunoregulation
- Field of Research: Inflammation/Immunology; Cancer
- Assay Protocol: https://www.medchemexpress.com/diABZI_STING_agonist-1_Tautomerism_trihydrochloride.html
- Purity: 99.92
- Solubility: DMSO : 90 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)
- Smiles: O=C(C1=CC(C)=NN1CC)NC2=NC3=CC(C(N)=O)=CC(OC)=C3N2C/C=C/CN4C5=C(OCCCN6CCOCC6)C=C(C(N)=O)C=C5N=C4NC(C7=CC(C)=NN7CC)=O.Cl.Cl.Cl
- Molecular Weight: 959.32
- References & Citations: [1]Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Nov 7.ACS Infect Dis. 2022 Feb 8.|Am J Cancer Res. 2023 May 30;13(5):2055-2065.|Cancer Lett. 20 August 2022, 215885.|Cancer Lett. 2024 Jun 21:217081.|Cell Death Dis. 2022 Jul 28;13(7):653.|Cell Immunol. 2021, 104384.|Exp Hematol Oncol. 2024 Aug 5;13(1):77.|Front Immunol. 2020 Jul 8;11:1430.|Front Pharmacol. 2023 Apr 4;14:1160445.|J Bone Miner Res. 2024 Jun 14:zjae093.|J Ethnopharmacol. 2024 Aug 17:118661.|J Invest Dermatol. 2021 Sep 24;S0022-202X(21)02227-2.|Mol Cell. 2023 Apr 14;S1097-2765(23)00243-5.|Nat Nanotechnol. 2021 Sep 30.|OncoImmunology. 2022 Feb 1;11(1):2030021.|PLoS One. 2021 Oct 27;16(10):e0258989.|Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120.|Protein Cell. 2021 Oct 22;1-21.|Sci China Life Sci. 2024 Aug 22.|Sci Rep. 2022 Oct 24;12(1):17827.|Thorac Cancer. 2022 May; 13(9): 1361–1368.|Biomed Pharmacother. 2024 Jan 2:171:116007.|Cancer Lett. 2024 May 1:589:216836.|Cell Death Differ. 2023 Nov 25.|Chin Herb Med. 2024 Jul.|Chin Med. 2024 Aug 15;19(1):107.|Genes Dis. 2023 Sep 2.|Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):13.|J Exp Med. 2021 Feb 1;218(2):e20200887.|University of California San Diego. 2023
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: No Development Reported